John Fesko Sells 669 Shares of Natera, Inc. (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) insider John Fesko sold 669 shares of Natera stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of $159.60, for a total value of $106,772.40. Following the completion of the sale, the insider now directly owns 114,142 shares in the company, valued at $18,217,063.20. This represents a 0.58 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Natera Stock Performance

Shares of NTRA stock opened at $160.26 on Friday. The company has a market capitalization of $21.16 billion, a price-to-earnings ratio of -91.06 and a beta of 1.63. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39. Natera, Inc. has a 52 week low of $58.53 and a 52 week high of $175.63. The company has a 50-day simple moving average of $150.16 and a 200 day simple moving average of $127.78.

Natera (NASDAQ:NTRA) last posted its earnings results on Tuesday, November 12th. The medical research company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.57) by $0.31. The company had revenue of $439.80 million for the quarter, compared to the consensus estimate of $361.43 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The firm’s revenue for the quarter was up 63.9% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.95) earnings per share. On average, sell-side analysts predict that Natera, Inc. will post -1.61 earnings per share for the current year.

Institutional Investors Weigh In On Natera

A number of institutional investors have recently modified their holdings of NTRA. Farallon Capital Management LLC raised its stake in Natera by 13.6% in the 2nd quarter. Farallon Capital Management LLC now owns 4,460,557 shares of the medical research company’s stock worth $483,034,000 after purchasing an additional 532,874 shares in the last quarter. Wellington Management Group LLP increased its holdings in shares of Natera by 205.4% during the third quarter. Wellington Management Group LLP now owns 2,800,263 shares of the medical research company’s stock worth $355,493,000 after purchasing an additional 1,883,481 shares during the period. Massachusetts Financial Services Co. MA raised its position in shares of Natera by 3.6% in the third quarter. Massachusetts Financial Services Co. MA now owns 2,482,818 shares of the medical research company’s stock valued at $315,194,000 after buying an additional 85,236 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Natera by 7.4% in the third quarter. Geode Capital Management LLC now owns 2,090,480 shares of the medical research company’s stock valued at $265,747,000 after buying an additional 143,825 shares during the period. Finally, Duquesne Family Office LLC grew its position in Natera by 2.4% during the second quarter. Duquesne Family Office LLC now owns 1,974,880 shares of the medical research company’s stock worth $213,860,000 after buying an additional 45,500 shares in the last quarter. Institutional investors own 99.90% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the company. Leerink Partners lifted their target price on Natera from $140.00 to $150.00 and gave the company an “outperform” rating in a research report on Thursday, October 17th. Piper Sandler boosted their price objective on shares of Natera from $150.00 to $200.00 and gave the stock an “overweight” rating in a research report on Monday, November 18th. The Goldman Sachs Group raised their target price on shares of Natera from $125.00 to $140.00 and gave the company a “buy” rating in a research report on Wednesday, October 16th. TD Cowen boosted their price target on shares of Natera from $155.00 to $175.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. Finally, Robert W. Baird raised their price objective on Natera from $120.00 to $160.00 and gave the company an “outperform” rating in a report on Wednesday, November 13th. One analyst has rated the stock with a sell rating and fifteen have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $152.67.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.